Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesAvalo Therapeutics Inc

Avalo Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
8.51 USD 1.35 ( 18.85%)
Last update at 2026-11-11T21:00:00Z
VOLUME
1837066
Market Cap
334.08M

Momentum Score

…

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
7.17
Low
8.55
High
52 Week Price Range
3.39
Low
20.72
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Avalo Therapeutics is a clinical-stage biotechnology company developing therapeutic candidates intended to address unmet medical needs in immune and inflammatory disorders. Long-term growth could be driven by pipeline advancement through regulatory milestones, strategic partnerships, and eventual commercialization of approved products, which may benefit investors seeking exposure to clinical-stage biotech innovation.

The most important risks include a high probability of clinical or regulatory failure, the need for additional financing before meaningful revenue, commercialization uncertainty, and potential shareholder dilution.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
7.16
Dividend Yield
-
Revenue TTM
0.06M
Revenue Per Share
0.00
Gross Profit TTM
-35.29M
Debt / Equity
0.03
ROE
-72.44%
Net Debt
-13.43M
ROCE
-70.78%
Diluted EPS TTM
-5.84

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -78.09M -35.02M -31.53M -41.63M -84.55M
Net income -78.26M -35.13M -31.54M -41.66M -84.35M
Selling general administrative 22.43M 16.45M 10.27M 20.64M 21.83M
Selling and marketing expenses 0.47M 0.79M 0.03M 0.08M 2.83M
Gross profit -0.28M 0.81M 0.64M 14.62M 3.91M
Reconciled depreciation 0.34M 0.17M 0.15M 0.17M 1.66M
Ebit -73.27M -68.51M -23.44M -37.44M -82.13M
Ebitda -72.92M -68.34M -23.29M -37.42M -80.59M
Depreciation and amortization 0.34M 0.17M 0.16M 0.02M 1.55M
Operating income -72.92M -68.51M -27.35M -37.44M -82.13M
Other operating expenses 72.98M 68.95M 29.27M 55.49M 87.53M
Interest expense - 3.32M 3.42M 4.17M 2.39M
Tax provision 0.17M 0.11M 0.03M 0.03M -0.20M
Net interest income 4.35M 3.32M -4.45M -4.17M -2.39M
Income tax expense 0.17M 0.11M 0.01M 0.03M -0.20M
Total revenue 0.06M 0.44M 1.92M 18.05M 5.40M
Total operating expenses 72.98M 69.32M 27.99M 52.06M 86.04M
Cost of revenue 0.34M -0.37M 1.28M 3.43M 1.49M
Total other income expense net -5.17M 33.50M -4.18M -4.19M -2.41M
Discontinued operations - - - - -0.03M
Net income from continuing ops -78.26M -35.13M -33.19M -41.66M -84.35M
Net income applicable to common shares - - - - -84.38M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 116.46M 150.73M 20.99M 33.37M 80.21M
Intangible assets - - - - 0.04M
Other current assets 6.95M 3.73M 0.84M 1.29M 2.37M
Total liab 33.41M 17.70M 13.69M 44.28M 57.13M
Total stockholder equity 83.05M 133.03M 7.30M -10.91M 23.08M
Other current liab 12.41M 6.11M 3.63M 13.21M 0.01M
Common stock 0.02M 0.01M 0.00M 0.01M 0.11M
Capital stock 0.02M 0.01M 0.00M 0.01M 0.11M
Retained earnings -448.52M -370.26M -335.13M -303.82M -262.17M
Other liab - - - 6.97M 4.41M
Good will 10.50M 10.50M 10.50M 14.41M 14.41M
Other assets - - 0.00M - 1.23M
Cash 15.86M 134.55M 7.42M 13.17M 54.59M
Total current liabilities 12.94M 6.96M 4.62M 22.11M 19.89M
Current deferred revenue - - - 0.09M 16.02M
Net debt -13.43M -133.98M -3.51M 6.24M -21.75M
Short term debt 0.39M 0.57M 0.54M 5.93M 0.48M
Short long term debt - - - 5.93M -
Short long term debt total 2.43M 0.57M 3.90M 19.42M 32.83M
Other stockholder equity 531.49M 503.29M 342.44M 292.90M 285.13M
Property plant equipment - - - 2.41M 2.69M
Total current assets 105.29M 138.89M 8.39M 16.42M 61.84M
Net tangible assets - - - -25.32M 8.63M
Short term investments 82.48M 0.00M - - -
Net receivables - 0.61M 0.14M 1.92M 4.80M
Long term debt - - - 13.49M 32.83M
Inventory - - 0.00M 0.02M 0.04M
Accounts payable 0.14M 0.28M 0.45M 2.88M 3.37M
Accumulated other comprehensive income 0.07M - - - -
Non currrent assets other 0.21M 0.13M 0.13M 0.13M 1.23M
Non current assets total 11.17M 11.84M 12.60M 16.95M 18.37M
Capital lease obligations 0.39M 0.57M 0.54M 0.53M 0.48M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -81.72M 0.36M -0.13M -0.10M -0.11M
Change to liabilities - - - 0.00M 0.80M
Total cashflows from investing activities -81.72M 0.36M -0.13M -0.10M -0.11M
Net borrowings - 0.00M -21.24M -14.81M 32.90M
Total cash from financing activities 14.59M 175.85M 25.04M -14.70M 106.76M
Change to operating activities - - - 4.09M 0.96M
Net income -78.26M -35.13M -31.54M -41.66M -84.38M
Change in cash -118.59M 127.15M -5.77M -41.55M 35.76M
Begin period cash flow 134.70M 7.55M 13.32M 54.86M 19.11M
End period cash flow 16.11M 134.70M 7.55M 13.32M 54.86M
Total cash from operating activities -51.46M -49.06M -30.68M -26.75M -70.89M
Issuance of capital stock 14.76M 115.62M 46.25M 0.03M 71.93M
Depreciation 0.34M 0.17M 0.16M 0.17M 1.66M
Other cashflows from investing activities 0.69M 0.36M 0.03M - -
Dividends paid - - - 14.81M -
Change to inventory - 0.00M 0.02M 0.02M -0.04M
Change to account receivables - -0.47M 1.78M 1.06M 1.12M
Sale purchase of stock 0.02M 0.07M 0.07M 0.07M 0.37M
Other cashflows from financing activities -0.51M 60.22M 0.07M 14.81M 34.47M
Change to netincome - - - - 8.19M
Capital expenditures 0.00M 0.00M 0.16M 0.10M 0.11M
Change in working capital 3.84M -4.71M -9.24M 4.77M 2.84M
Stock based compensation 13.62M 5.85M 3.48M 7.55M 8.17M
Other non cash items 8.83M -15.35M 6.46M 2.39M 0.79M
Free cash flow -51.46M -49.06M -30.84M -26.85M -71.00M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AVTX
Avalo Therapeutics Inc		 1.35
18.85%		 8.51 - - 5662.35 4.02 4002.28 -0.19
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Avalo Therapeutics Inc

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

1500 Liberty Ridge Drive, Wayne, PA, United States, 19087

410 522 8707

https://www.avalotx.com

33

Name Title Year Born
Dr. Garry A. Neil M.D. Chairman, Pres & CEO 1954
Dr. Solomon H. Snyder M.D. Founder and Chairman of Scientific Advisory Board 1939
Dr. Barbara S. Slusher Ph.D. Founder and Member of Scientific Advisory Board 1965
Mr. Christopher Ryan Sullivan Chief Financial Officer 1985
Dr. Lisa Hegg Ph.D. Sr. VP of Program Management & Corp. Infrastructure NA
Mr. Maxim Jacobs C.F.A. VP of Investor Relations NA
Dr. Stephen Thomas Ph.D. VP & Head of Discovery NA
Ms. Colleen Matkowski Sr. VP of Global Regulatory Affairs & Quality Assurance NA
Dr. Dino C. Miano Ph.D. Sr. VP of CMC & Technical Operations NA
Dr. Blake M. Paterson M.D. Scientific Advisor 1957

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…